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FIGURE 1. GFP expression in retina with AAV2/5-hGRK1-GFP virus. The virus is AAV2/5 and we are using a reporter gene, in this case green fluorescent protein-GFP, to determine which
cells in the retina are modified by the virus. For this study, we are using a human rhodopsin kinase gene promoter (hGRK1) to direct expression in the rod cells (here they have turned
green). The red cells are cones which are not tranduced by this vector construct and are identified with an antibody that recognises a cone-specific protein called cone arrestin. For
XLRP where cones as well as rods are affected, we also have to use a separate vector construct to direct expression to cones; in this case the human red cone opsin promoter.
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Window into retinal studies
Professor Gustavo Aguirre discusses the context of his research studies at the University of
Pennsylvania, which are currently concentrating on the degenerative disease, retinitis pigmentosa
Firstly, can you outline the broader aims and
objectives of your research?

been made in this regard, and any further
challenges clinical trials have thrown up?

There are many inherited diseases that have
been found to affect the retina and cause
blindness. Beyond finding the disease-causing
mutations, the aim of the research is to
understand how these diseases develop, and
then investigate the pathways that link the
mutation to the death of the visual cells, and
determine if these are specific or common to one
or more diseases. From this, we seek to develop
intelligent therapies that can be used in treating
the retinal diseases. Most of our work uses dog
models; in the past we have used cats, monkeys
and humans, but the work we do to develop
translational studies primarily involves dogs.

The Phase 1 studies in human patients have
confirmed that treatment of the study population
is safe which is the primary goal of any Phase 1
clinical trial. In addition, the studies have shown
efficacy in some patients. What we now need
is to determine the patient population that is
amenable to treatment, and the long-term safety
and efficacy in treated patients.

Can you provide an overview of the discovery of
X-linked retinitis pigmentosa (XLRP) diseases?
There are several retinal diseases in humans that
are known to have X-linked inheritance. There are
only two where the gene has been found: RP-3
and RP-2. The pioneering work on the mapping of
these diseases was done in the UK by Professors
Alan Wright (University of Edinburgh) and Shomi
Bhattacharya (Institute of Opthalmology)
beginning in the 1980s. It took a long time to
refine the disease intervals, and many groups
were working on this difficult area. Eventually, the
Wright and Meitinger groups published a seminal
paper identifying a very complex gene called
RPGR (Retinitis Pigmentosa GTPase Regulator).
They also found part of the gene which had
previously been very difficult to sequence. This
DNA region – ORF-15 – accounted for about 70
per cent of mutations in patients with RPGR. After
this finding, my team collaborated intensely with
Wright and found that dogs had the mutation in
the same ORF15 region as patients. When you
take most populations of patients with X-linked
RP, up to 70 or 80 per cent have mutations in
RPGR. Thus it is recognised as the most common
cause of X-linked RP. It is a very severe problem,
not least because the regions in questions are very
difficult to clone and sequence.
The first gene therapy clinical trials in human
patients affected with a severe form of
childhood blindness were reported 2008. Can
you highlight the developments which have
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In the studies with LCA-affected dogs over the
past 10 years, we have shown stable correction
and safety over this period of time. What we
still need to know are the structural correlates
of the restored function. In other words, does
the treated retina remain normal and, if so,
can it restore the chemical connections with
other cells that ultimately are responsible for
transmitting the visual information to the brain.
The new studies under the direction of Dr András
Komáromy use a different model of severe visual
impairment – achromatopsia – that occurs at
birth. Patients with this severe disease have an
aversion to light; they are totally blind in bright
light; their fovea and macula – which contain
the cone cells that enable colour vision and high
visual acuity – do not function normally. We
have published a paper which details that this
disease can be cured and, with collaborators at
the University of Florida, are planning to develop
clinical trials for this disease. In this disease, the
studies are directed at treating cones – the main
class of cells involved in macular degeneration.
If we can develop a treatment targeting cones,
there is the exciting possibility that we can treat
other diseases also.
What major, long-standing challenges does
your field of research present?
From a scientific point of view, a main challenge
now is in eliminating proteins that have an adverse
effect on tissue, not only in relation to X-linked
RP, but other dominant diseases in which the
actual genetic defect produced a protein that has
a deleterious affect on the retinal photoreceptors.
One such disease is caused by mutations in the
rhodopsin gene which is an extremely common
cause of autosomal dominant RP.

Many disease-causing mutations that are
inherited as dominant or X-linked result in
what is known as gain-of-function, where the
abnormal proteins produced cause disease.
For therapy, you first must prevent production
of the abnormal protein,and then replace it
with the normal version. In the X-linked RP
model, which is applicable to a large number of
dominant diseases, the need to eliminate the
undesirable mutant protein is a challenge of
utmost importance.
To what extent has genome sequencing been
integral in enabling the team to identify likely
targets for intervention, and can you outline the
support offered by the Penn Genome Frontiers
Institute (PGFI)?
The progress made in this regard is remarkable.
When I first started work in this field in 1992, there
were absolutely no genome resources available
for the dog. So we had to carry out cloning for
ourselves, taking information gained from the
cloning of genes in mice, cows and humans. When
I look over the lab books, I recall that people
would spend several years cloning genes; today
you simply access the information through a web
browser. We can use SNP-chips to track diseases or
identify new diseases, and arrays to look at gene
expression. The resources available at the PGFI
have been critical in providing the infrastructure
and resources needed to do this work.
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Seeing is believing
A research team based at the University of Pennsylvania are conducting
essential research which could lead to promising therapies for X-linked
retinitis pigmentosa, an hereditary disease that leads to blindness
FOR THE BEST part of two decades, Dr
Gustavo Aguirre of the School of Veterinary
Medicine at the University of Pennsylvania,
Philadelphia, has dedicated his research efforts
to the long-term development of therapies for
degenerative retinal diseases. Presently, Aguirre
and his collaborators are conducting studies in
relation to retinitis pigmentosa (RP) linked to
the X-chromosome. RP represents a group of
hereditary and degenerative eye conditions that
invariably induce total blindness in patients. In
general terms, this group of diseases is associated
with dystrophies of the photoreceptors of the
retina and/or the pigment epithelium.
Aguirre and his associate, Dr William Beltran, are
employing dog models in identifying the genes and
pathways associated with a form of RP known as
X-linked PRA2 (XLPRA2). This naturally occurring
canine disease is a close correlate of early-onset
XLRP in humans. This work has great potential for
translational studies to harness a novel therapy for
XLRP caused by mutations in the ORF-15 region of
the RPGR gene. Significantly for XLRP, mutations in
this gene account for 8-10 and 15-20 per cent of
early onset retinal diseases in the U.S. and Europe
respectively. With this in mind, it is clearly manifest
that Aguirre’s studies bear enormous potential and
relevance in clinical terms; however, the industry
and dedication shown by Aguirre and his team up
to this point also warrant attention.

RP STUDIES IN FOCUS
Restoring vision in patients is the overall goal of
basic and applied research in this field. However, in
past decades, a significant proportion of studies and
investigations have focused on slowing the rate of
vision loss in patients with RP through nutritional
supplementation, because of the limited availability
of therapeutic alternatives. Another approach to
combating the disease has seen neuroprotective
agents, such as CNTF, being transported to the
retina through ECT technology, which utilises
genetically engineered cells that are encapsulated
and placed in the eye. Whilst studies employing
these techniques have delivered important findings,
there is consensus that advancements in molecular
science are integral to understanding the causes of
RP. This, in turn, has engendered further hope for
the development of effective treatment options.
Molecular science has enabled significant progress
to be made in identifying loci and genes linked to
retinal dysfunction; unfortunately, this progress has
not been mirrored to the same extent where the
development of treatments is concerned. Indeed,

whilst encouraging findings have emerged from a
large number of experimental studies in animals,
there is still a paucity of approved treatments for
patients diagnosed with RP.
However, work recently undertaken by Aguirre’s
group and associates has garnered extremely
encouraging results that have unlocked potential
human therapies, currently in Phase I trials by
various groups of investigators in Europe and the
U.S. The study relates to a mutation in the RPE65
gene in patients with a form of RP known as Leber
congenital amaurosis (LCA).
In light of this notable achievement, Aguirre’s
team remain focused and determined to
continue to deliver important contributions in the
development of therapies for RP; they envisage
each investigation as part of an incremental process
where knowledge relating to the mechanisms
which lead to RP is steadily enhanced and used in
formulating new treatments. As such, the success
registered by the team in regard to RPE65-LCA has
provided a basis from which they can explore more
complex disorders. In this sense, the team’s latest
proposal regarding RPGR-XLRP marks their next
developmental stage in addressing forms of RP.

CURRENT INVESTIGATIONS
While a considerable proportion of patients
with retinal diseases carry mutations in the
RPGR gene, significant gaps persist in our
understanding of the function of the protein, as
well as the molecular mechanisms that lead to
photoreceptor degeneration.
In addressing this issue, part of Aguirre and
his investigators’ latest research involves the
identification of genes and pathways associated
with Retinal Dysfunction (RD) in dogs affected
with XLPRA2, also known as RPGR2. This is a
canine model of early-onset XLRP caused by an
RPGR exon ORF15 microdeletion. The connection
between RPGR2 in dogs and RPGR in humans is
extremely useful: should the team determine that
the molecular mechanisms underlying XLPRA2 in
dogs are the same as those of XLRP in humans, it
is anticipated that therapies proven effective in
canine models will be likely to induce comparable
effects in patients.
The team’s investigations in canine models will
run in parallel with a comprehensive study in
patients seeking to enhance knowledge regarding
the range and history of XLRP. This corresponding
study, carried out by Drs Samuel Jacobson and
Artur Cideciyan at the University of Pennsylvania,
WWW.RESEARCHMEDIA.EU 109

INTELLIGENCE
MODELS OF X-LINKED RETINITIS PIGMENTOSA
OBJECTIVES
• To develop specific gene-based therapies for RPGRXLRP past the proof-of-principle stage so that
clinical trials are then generated
• To assist collaborators, Drs S Jacobson and A
Cideciyan, to conduct prospective studies in RPGRXLRP patients to assess the feasibility or facility of
translating pre-clinical therapy to the clinic
• To carry out complementary in vivo studies in the
canine model to quantify photoreceptor laminar
structure and function, with emphasis on the central
retina, at comparable disease stages as the patients,
to establish the morphological/immunocytochemical
correlates to the observations made in dogs that can
be extrapolated to patients

PARTNERS
School of Veterinary Medicine, University of
Pennsylvania:
William A Beltran, DVM, PhD
Sem Genini, PhD
András M Komáromy, DVM, PhD (achromatopsia)
Scheie Eye Institute, School of Medicine,
University of Pennsylvania:
Samuel G Jacobson, MD, PhD
Artur V Cideciyan, PhD
Departments of Ophthalmology, Molecular
Genetics and Microbiology, School of Medicine,
University of Florida:
William W Hauswirth, PhD
Alfred S Lewin, PhD

will aim towards the development of a
set of outcome measures tailored to preclinical treatment strategies. The concept of
running concurrent studies is ambitious; yet,
given the capabilities of the investigators, it
would seem that their bold objective is wellplaced and feasible.

A MULTIDISCIPLINARY APPROACH
The complexity and breadth of this
research programme requires the expertise
of a team with proven experience in
translational research. The group members’
collective ability to engage in throughput
investigations – dealing with science-based
ideas to clinical application of therapies – is
perhaps epitomised in their harnessing of an
effective treatment for LCA. The antecedent
study, in which the team translated dog and
murine results to human RPE65-LCA, has
cultivated a greater appreciation that proofof-principle treatments in animal models
generate a multitude of questions regarding
exact human application.
Crucially, over the years Aguirre has forged
and enjoyed fruitful partnerships with
other leading researchers and clinicians
across the U.S. and beyond. In regard
to interaction and studies in patient
populations, the research benefits from
cooperative efforts, as Aguirre highlights:
“Drs Samuel Jacobson and Artur Cideciyan,
collaborators at the Scheie Institute
who also run the Center for Retinal
Degenerations here at the University of

Pennsylvania, are really crucial in this
respect because they see the actual patient
population”. He continues: “They have
a great interest in the diseases in dogs,
enabling them to better delineate these
diseases in humans”.
Furthermore, the development of virus
vectors – which are required to transport
genes to the retina – is conducted by
external partners, Drs William Hauswirth
and Alfred Lewin, at the Departments of
Ophthalmology, Molecular Genetics and
Microbiology, and the Powell Gene Therapy
Center, University of Florida. This valuable
collaboration is pivotal to the advancement
of studies which require specific targeting
of the retinal cells, elimination of the
mutant gene product and replacement
with a normal copy of the gene.
Looking beyond the current research
programme, Aguirre is excited by the
prospects and promise held in the laboratories
at Penn. His praise is unreserved: “It is a joy
to have here at Penn a group of scientists
who are young, talented, productive and
enthusiastic, and it is reassuring to know that
they will be here to continue the work in the
long term,” he comments.
The tools, it would appear, are in place; it
will only be a matter of time before Aguirre
and his wider team make further valued
contributions to this field of enduring and
essential research.
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GUSTAVO D AGUIRRE is Professor of Medical
Genetics and Ophthalmology at The School of
Veterinary Medicine, University of Pennsylvania. He
earned undergraduate, veterinary, and doctoral degrees
at the University of Pennsylvania, and joined the faculty
at Penn in 1973. Dr Aguirre has received numerous
awards, including the Foundation Fighting Blindness
Trustee Award, Scientist of the Year, and he was a
co-recipient of the Paul Kayser International Award
in Retina Research. He was recently elected Fellow,
Association for Research in Vision and Ophthalmology.
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András M Komáromy, DVM, PhD (achromatopsia) and William A Beltran, DVM, PhD
from the School of Veterinary Medicine, University of Pennsylvania

